<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en-US"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>savvyr: Survival Analysis for AdVerse Events with VarYing Follow-Up Times — savvyr-package • savvyr</title><script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet"><script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/font-awesome-6.5.2/css/all.min.css" rel="stylesheet"><link href="../deps/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet"><script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="savvyr: Survival Analysis for AdVerse Events with VarYing Follow-Up Times — savvyr-package"><meta name="description" content="
The SAVVY (Survival Analysis for AdVerse Events with VarYing Follow-Up Times) project is a consortium of academic and pharmaceutical industry partners that aims to improve the analyses of adverse event (AE) data in clinical trials through the use of survival techniques appropriately dealing with varying follow-up times and competing events, see Stegherr, Schmoor, Beyersmann, et al. (2021) doi:10.1186/s13063-021-05354-x
. Although statistical methodologies have advanced, in AE analyses often the incidence proportion, the incidence density or a non-parametric Kaplan-Meier estimator are used, which either ignore censoring or competing events. This package contains functions to easily conduct the proposed improved AE analyses."><meta property="og:description" content="
The SAVVY (Survival Analysis for AdVerse Events with VarYing Follow-Up Times) project is a consortium of academic and pharmaceutical industry partners that aims to improve the analyses of adverse event (AE) data in clinical trials through the use of survival techniques appropriately dealing with varying follow-up times and competing events, see Stegherr, Schmoor, Beyersmann, et al. (2021) doi:10.1186/s13063-021-05354-x
. Although statistical methodologies have advanced, in AE analyses often the incidence proportion, the incidence density or a non-parametric Kaplan-Meier estimator are used, which either ignore censoring or competing events. This package contains functions to easily conduct the proposed improved AE analyses."><meta property="og:image" content="https://openpharma.github.io/savvyr/logo.png"></head><body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top bg-light" data-bs-theme="light" aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">savvyr</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.1.2</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto"><li class="active nav-item"><a class="nav-link" href="../reference/index.html">Reference</a></li>
<li class="nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-articles" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Articles</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-articles"><li><a class="dropdown-item" href="../articles/introduction.html">Introduction to `savvyr`</a></li>
  </ul></li>
<li class="nav-item"><a class="nav-link" href="../news/index.html">Changelog</a></li>
      </ul><ul class="navbar-nav"><li class="nav-item"><a class="external-link nav-link" href="https://github.com/openpharma/savvyr"><span class="fa fa-github"></span></a></li>
      </ul></div>


  </div>
</nav><div class="container template-reference-topic">
<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="../logo.png" class="logo" alt=""><h1>savvyr: Survival Analysis for AdVerse Events with VarYing Follow-Up Times</h1>
      <small class="dont-index">Source: <a href="https://github.com/openpharma/savvyr/blob/main/R/savvyr-package.R" class="external-link"><code>R/savvyr-package.R</code></a></small>
      <div class="d-none name"><code>savvyr-package.Rd</code></div>
    </div>

    <div class="ref-description section level2">
    <p></p>
<p>The SAVVY (Survival Analysis for AdVerse Events with VarYing Follow-Up Times) project is a consortium of academic and pharmaceutical industry partners that aims to improve the analyses of adverse event (AE) data in clinical trials through the use of survival techniques appropriately dealing with varying follow-up times and competing events, see Stegherr, Schmoor, Beyersmann, et al. (2021) <a href="https://doi.org/10.1186/s13063-021-05354-x" class="external-link">doi:10.1186/s13063-021-05354-x</a>
. Although statistical methodologies have advanced, in AE analyses often the incidence proportion, the incidence density or a non-parametric Kaplan-Meier estimator are used, which either ignore censoring or competing events. This package contains functions to easily conduct the proposed improved AE analyses.</p>
    </div>


    <div class="section level2">
    <h2 id="see-also">See also<a class="anchor" aria-label="anchor" href="#see-also"></a></h2>
    <div class="dont-index"><p>Useful links:</p><ul><li><p><a href="https://openpharma.github.io/savvyr/">https://openpharma.github.io/savvyr/</a></p></li>
<li><p>Report bugs at <a href="https://github.com/openpharma/savvyr/issues" class="external-link">https://github.com/openpharma/savvyr/issues</a></p></li>
</ul></div>
    </div>
    <div class="section level2">
    <h2 id="author">Author<a class="anchor" aria-label="anchor" href="#author"></a></h2>
    <p><strong>Maintainer</strong>: Thomas Kuenzel <a href="mailto:thomas.kuenzel@roche.com">thomas.kuenzel@roche.com</a></p>
<p>Authors:</p><ul><li><p>Kaspar Rufibach <a href="mailto:kaspar.rufibach@roche.com">kaspar.rufibach@roche.com</a></p></li>
<li><p>Regina Stegherr <a href="mailto:regina.stegherr@uni-ulm.de">regina.stegherr@uni-ulm.de</a></p></li>
<li><p>Daniel Sabanés Bové <a href="mailto:daniel@rconis.com">daniel@rconis.com</a></p></li>
</ul><p>Other contributors:</p><ul><li><p>F. Hoffmann-La Roche AG [copyright holder, funder]</p></li>
<li><p>Universität Ulm [copyright holder, funder]</p></li>
</ul></div>

  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside></div>


    <footer><div class="pkgdown-footer-left">
  <p>Developed by Thomas Kuenzel, Kaspar Rufibach, Regina Stegherr, Daniel Sabanés Bové, F. Hoffmann-La Roche AG, Universität Ulm.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.2.</p>
</div>

    </footer></div>





  </body></html>

